VTYX Ventyx Biosciences Inc
Price (delayed)
$1.06
Market cap
$75.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.97
Enterprise value
$57.96M
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2
Highlights
Ventyx Biosciences's EPS has increased by 40% YoY and by 17% from the previous quarter
VTYX's net income is up by 30% year-on-year and by 11% since the previous quarter
VTYX's quick ratio has surged by 50% year-on-year but it is down by 24% since the previous quarter
Ventyx Biosciences's equity has decreased by 9% from the previous quarter but it has increased by 4.1% YoY
Key stats
What are the main financial stats of VTYX
Market
Valuations
Earnings
Shares outstanding
71.13M
Market cap
$75.4M
Enterprise value
$57.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$148.45M
Net income
-$135.12M
EBIT
-$135.12M
EBITDA
-$133.77M
Free cash flow
-$131.11M
Per share
Balance sheet
Liquidity
EPS
-$1.97
EPS diluted
-$1.97
Free cash flow per share
-$1.91
Book value per share
$3.59
Revenue per share
$0
TBVPS
$4.04
Total assets
$276.56M
Total liabilities
$22.52M
Debt
$10.79M
Equity
$254.05M
Working capital
$216.85M
Debt to equity
0.04
Current ratio
17.97
Quick ratio
17.09
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-44.3%
Return on equity
-48.2%
Return on invested capital
-58.1%
Return on capital employed
-51.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTYX stock price
How has the Ventyx Biosciences stock price performed over time
Intraday
-0.93%
1 week
-13.11%
1 month
-32.91%
1 year
-79.77%
YTD
-51.6%
QTD
-7.83%
Financial performance
How have Ventyx Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$148.45M
Net income
-$135.12M
Gross margin
N/A
Net margin
N/A
VTYX's net income is up by 30% year-on-year and by 11% since the previous quarter
The operating income is up by 29% year-on-year and by 11% since the previous quarter
Growth
What is Ventyx Biosciences's growth rate over time
Valuation
What is Ventyx Biosciences stock price valuation
P/E
N/A
P/B
0.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Ventyx Biosciences's EPS has increased by 40% YoY and by 17% from the previous quarter
The price to book (P/B) is 57% lower than the last 4 quarters average of 0.7
Ventyx Biosciences's equity has decreased by 9% from the previous quarter but it has increased by 4.1% YoY
Efficiency
How efficient is Ventyx Biosciences business performance
Ventyx Biosciences's ROE has increased by 23% YoY and by 12% from the previous quarter
The company's return on assets rose by 23% YoY and by 11% QoQ
The company's return on invested capital rose by 21% YoY and by 14% QoQ
Dividends
What is VTYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTYX.
Financial health
How did Ventyx Biosciences financials performed over time
Ventyx Biosciences's current ratio has soared by 51% YoY but it has decreased by 24% from the previous quarter
VTYX's quick ratio has surged by 50% year-on-year but it is down by 24% since the previous quarter
The debt is 96% smaller than the equity
The debt to equity is down by 20% YoY
The debt is down by 14% year-on-year and by 2.2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.